Vor Biopharma
VOR
18.20
-0.58
-3.09%
Vor Biopharma
US · VOR
#3175 by market cap
Listed 2021
18.20
-0.58
-3.09%
Live - 5344 symbols - heartbeat 521s ago
· 2026-10-08 09:59
Pre-market
18.64
-0.75%
After-hours
18.78
0.00%
Overnight
18.80
+0.11%
- Market cap
- 1.08B
- P/E (TTM)i
- 1.58
- P/Bi
- -5.38
- EPSi
- -70.50
- Div yieldi
- 0.00%
- 52W posi
- 43%
Reader sentiment
Are you bullish or bearish on VOR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.9 percentage points.
Institutional ownership
- Held by institutions
- 98.32% -0.91pp
- Institutions
- 129 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund46.81%
Mutual Fund31.91%
Hedge Fund18.19%
Individual/Insider2.00%
Public Company1.03%
Private Company0.20%
Insurance Company0.14%
Top holders as of 2026-07-31
FMR
11.00% · 6.51M sh
TCG Crossover Management, LLC
9.59% · 5.67M sh
RA Capital Management, L.P.
7.61% · 4.50M sh
Forbion Capital Partners B.V.
6.96% · 4.12M sh
BlackRock
5.86% · 3.47M sh
VERVE CAPITAL, Inc.
5.77% · 3.41M sh
VR Management, LLC
5.14% · 3.04M sh
State Street Global Advisors
4.42% · 2.62M sh
Frazier Life Sciences Management, LP
4.30% · 2.54M sh
Vanguard Capital Management, LLC
4.03% · 2.39M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 19 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| Reid Hoffman | -- | 1.97% |
| Robert Ang | Chief Executive Officer | 0.01% |
| Tirtha Chakraborty | Chief Scientific Officer | 0.01% |
| Matthew Patterson | Independent Chairperson | 0.00% |
| Sven Lundberg | Independent Director | 0.00% |
| Han Choi | Chief Financial Officer | 0.00% |
| Eyal Attar | Chief Medical Officer | 0.00% |
| David Lubner | Independent Director | -- |
| Sarah Watt Reed | Independent Director | -- |
| RA Capital Management, L.P. | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | RA Capital Management, L.P. | -- | Derivative Exercise and Retained | +500 | $12.80 |
| 2026-08-23 | RA Capital Management, L.P. | -- | Derivative Exercise and Retained | +1,500 | $3.74 |
| 2026-07-15 | RA Capital Management, L.P. | -- | Derivative Exercise and Sale | -213 | $0.00–19.75 |
| 2026-07-15 | RA Capital Management, L.P. | -- | Derivative Exercise and Retained | +2,099,787 | $0.00 |
| 2026-07-06 | David Zaccardelli | Director | Other Derivative Acquisition | +42,658 | $20.10 |
| 2026-06-10 | RA Capital Management, L.P. | -- | Other Derivative Acquisition | +57,162 | $14.09 |
| 2026-06-10 | Michel Detheux | Director | Other Derivative Acquisition | +57,162 | $14.09 |
| 2026-06-10 | Sabretooth Capital Management, LLC | -- | Other Derivative Acquisition | +57,162 | $14.09 |
| 2026-06-10 | Daniella Beckman | Independent Director | Other Derivative Acquisition | +53,283 | $14.09 |
| 2026-06-10 | Andrew Levin | Director | Other Derivative Acquisition | +57,162 | $14.09 |
| 2026-06-10 | Alexander Cumbo | Director | Other Derivative Acquisition | +56,345 | $14.09 |
| 2026-06-10 | Fouad Namouni | Director | Other Derivative Acquisition | +56,549 | $14.09 |
| 2026-06-10 | Wouter Sebastian Joustra | Director | Other Derivative Acquisition | +57,162 | $14.09 |
| 2026-04-21 | RA Capital Management, L.P. | -- | Open Market Disposition | -165,150 | $15.77 |
| 2026-04-19 | RA Capital Management, L.P. | -- | Open Market Disposition | -630,374 | $15.77–16.28 |
| 2026-04-14 | RA Capital Management, L.P. | -- | Open Market Disposition | -737,989 | $15.97–16.15 |
| 2026-04-09 | RA Capital Management, L.P. | -- | Open Market Disposition | -484,932 | $15.75–16.91 |
| 2026-04-08 | RA Capital Management, L.P. | -- | Private Disposition | -135,201 | $16.59 |
| 2026-04-05 | RA Capital Management, L.P. | -- | Open Market Disposition | -849,257 | $16.51–19.06 |
| 2026-03-31 | Jeremy Sokolove | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:59:21 · For reference only, not investment advice and not tailored to your situation.